H.J. Hoffmann (Aarhus, Denmark), M. Gaga (Athens, Greece)
LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study
H. G Ortega, M. C Liu, I. D Pavord, G. B Brusselle, J. M. FitzGerald, A. Chetta, L. E Katz, O. N Keene, S. W Yancey, P. Chanez (Research Triangle Park, Baltimore, United States Of America; Oxford, Stockley Park, United Kingdom; Ghent, Belgium; Vancouver, Canada; Parma, Italy; Marseille, France)
|  |
LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study
E. Bel, S. Wenzel, P. Thompson, C. Prazma, O Keene, S. Yancey, H Ortega, I. Pavord (Amsterdam, Netherlands; Pittsburgh, Research Triangle Park, United States Of America; Crawley, Australia; Stockley Park, Oxford, United Kingdom)
| |
LATE-BREAKING ABSTRACT: Phase 2a randomized placebo-controlled trial of the oral prostaglandin D2 receptor (DP2/ CRTh2) antagonist QAW039 in eosinophilic asthma
S. Gonem, R. Berair, A. Singapuri, R. Hartley, M. Laurencin, G. Bacher, C. Lu, B. Holzhauer, M. Bourne, V. Mistry, I. Pavord, A. Mansur, A. Wardlaw, S. Siddiqui, R. Kay, C. Brightling (Leicester, Oxford, Birmingham, United Kingdom; Basel, Switzerland; East Hannover, United States Of America)
| |
LATE-BREAKING ABSTRACT: A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma
M. Castro, S. Wenzel, R. Kolbeck, D. Khatry, W. Christine, Y. Wu, R. van der Merwe, E. Bleecker (St. Louis, Pittsburgh, Gaithersburg, Winston-Salem, United States Of America)
|  |
LATE-BREAKING ABSTRACT: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic response
G. M. Gauvreau, L. P. Boulet, R. Leigh, D. W. Cockcroft, B. E. Davis, I. Mayers, J. M. FitzGerald, B. Dahlen, R. M. Watson, J. Milot, V. Swystun, L. Hui, A. S. Lantz, M. Bowen, J. Arm, S. Maahs, K. Meiser, P. Lowe, A. Skerjanec, C. Carlsten, K. Strandberg, K. J. Killian, M. Laviolette, A. Drollmann, P. M. O'Byrne (Hamilton, Québec, Calgary, Saskatoon, Edmonton, Vancouver, Canada; Stockholm, Sweden; Basel, Switzerland; East Hanover, United States Of America)
|  |
LATE-BREAKING ABSTRACT: Epigenetic inhibition of proliferation and inflammation in airway epithelium
B. van Groen, P. Brook, I. Adcock, A. Durham (Utrecht, Netherlands; London, United Kingdom)
| |
LATE-BREAKING ABSTRACT: IL-5-induced airways eosinophilia as a negative regulator of TLR7 expression may impair the interferon response to rhinovirus in allergic airways
A. Collison, L. Hatchwell, J. Girkin, K. Parsons, J. Li, J. Zhang, S. Phipps, D. Knight, N. W Bartlett, S. L Johnston, P. S Foster, P. A. B Wark, J. Mattes (Newcastle, Brisbane, Australia; Changchun, China; London, United Kingdom)
| |
LATE-BREAKING ABSTRACT: Phosphoinositide-dependent protein kinase-1 mediates inhibitory effects on eosinophils.
E. M. Sturm, G. P. Parzmair, B. Radnai, R. B. Frei, A. Heinemann (Graz, Austria)
| |